Switch theme
Sign up to access all valuation multiples
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
1993
794
LTM Revenue $390M
LTM EBITDA $45.1M
$335M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Laboratorio Reig Jofre has a last 12-month revenue (LTM) of $390M and a last 12-month EBITDA of $45.1M.
In the most recent fiscal year, Laboratorio Reig Jofre achieved revenue of $381M and an EBITDA of $40.6M.
Laboratorio Reig Jofre expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Laboratorio Reig Jofre valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $390M | XXX | $381M | XXX | XXX | XXX |
| Gross Profit | $230M | XXX | $220M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $45.1M | XXX | $40.6M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $25.1M | XXX | $16.9M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $14.5M | XXX | $11.7M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $40.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Laboratorio Reig Jofre's stock price is EUR 3 (or $4).
Laboratorio Reig Jofre has current market cap of EUR 256M (or $288M), and EV of EUR 299M (or $335M).
See Laboratorio Reig Jofre trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $335M | $288M | XXX | XXX | XXX | XXX | $0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Laboratorio Reig Jofre has market cap of $288M and EV of $335M.
Laboratorio Reig Jofre's trades at 0.9x EV/Revenue multiple, and 8.3x EV/EBITDA.
Equity research analysts estimate Laboratorio Reig Jofre's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Laboratorio Reig Jofre has a P/E ratio of 19.9x.
See valuation multiples for Laboratorio Reig Jofre and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $288M | XXX | $288M | XXX | XXX | XXX |
| EV (current) | $335M | XXX | $335M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 7.4x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBIT | 13.4x | XXX | 19.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.9x | XXX | 24.7x | XXX | XXX | XXX |
| EV/FCF | 39.9x | XXX | 28.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLaboratorio Reig Jofre's last 12 month revenue growth is 6%
Laboratorio Reig Jofre's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Laboratorio Reig Jofre's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Laboratorio Reig Jofre's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Laboratorio Reig Jofre and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laboratorio Reig Jofre acquired XXX companies to date.
Last acquisition by Laboratorio Reig Jofre was XXXXXXXX, XXXXX XXXXX XXXXXX . Laboratorio Reig Jofre acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Laboratorio Reig Jofre founded? | Laboratorio Reig Jofre was founded in 1993. |
| Where is Laboratorio Reig Jofre headquartered? | Laboratorio Reig Jofre is headquartered in Spain. |
| How many employees does Laboratorio Reig Jofre have? | As of today, Laboratorio Reig Jofre has 794 employees. |
| Is Laboratorio Reig Jofre publicy listed? | Yes, Laboratorio Reig Jofre is a public company listed on MAD. |
| What is the stock symbol of Laboratorio Reig Jofre? | Laboratorio Reig Jofre trades under RJF ticker. |
| When did Laboratorio Reig Jofre go public? | Laboratorio Reig Jofre went public in 2006. |
| Who are competitors of Laboratorio Reig Jofre? | Similar companies to Laboratorio Reig Jofre include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Laboratorio Reig Jofre? | Laboratorio Reig Jofre's current market cap is $288M |
| What is the current revenue of Laboratorio Reig Jofre? | Laboratorio Reig Jofre's last 12 months revenue is $390M. |
| What is the current revenue growth of Laboratorio Reig Jofre? | Laboratorio Reig Jofre revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Laboratorio Reig Jofre? | Current revenue multiple of Laboratorio Reig Jofre is 0.9x. |
| Is Laboratorio Reig Jofre profitable? | Yes, Laboratorio Reig Jofre is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Laboratorio Reig Jofre? | Laboratorio Reig Jofre's last 12 months EBITDA is $45.1M. |
| What is Laboratorio Reig Jofre's EBITDA margin? | Laboratorio Reig Jofre's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Laboratorio Reig Jofre? | Current EBITDA multiple of Laboratorio Reig Jofre is 7.4x. |
| What is the current FCF of Laboratorio Reig Jofre? | Laboratorio Reig Jofre's last 12 months FCF is $8.4M. |
| What is Laboratorio Reig Jofre's FCF margin? | Laboratorio Reig Jofre's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Laboratorio Reig Jofre? | Current FCF multiple of Laboratorio Reig Jofre is 39.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
